Calidi Biotherapeutics (CLDI) News Today $0.89 0.00 (-0.18%) Closing price 01/17/2025 04:00 PM EasternExtended Trading$0.90 +0.01 (+1.02%) As of 08:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Calidi Biotherapeutics (NYSE American: CLDI) Prices $4.25 Million Public OfferingJanuary 13, 2025 | theglobeandmail.comCalidi to present new data on systemic virotherapy RTNova platformJanuary 13, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025January 13, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces $4.25 Million Public Stock OfferingJanuary 13, 2025 | americanbankingnews.comCalidi Biotherapeutics Refiles Consolidated Financial Statements After Reverse Stock SplitJanuary 13, 2025 | americanbankingnews.comCalidi Biotherapeutics Prices Offering Of 5 Mln Shares At $0.85/Share, Stock FallsJanuary 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics slumps 29%, prices $4.25M stock offeringJanuary 10, 2025 | msn.comCalidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common StockJanuary 10, 2025 | globenewswire.comCalidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common StockJanuary 10, 2025 | globenewswire.comCalidi announces common stock offering, no amount givenJanuary 9, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Proposed Public OfferingJanuary 8, 2025 | globenewswire.comAllan Camaisa Sells 10,000 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) StockDecember 19, 2024 | insidertrades.comCalidi Biotherapeutics (NYSE American: CLDI) at the Forefront of Cancer Treatment InnovationDecember 13, 2024 | theglobeandmail.comCalidi Biotherapeutics prices $7.5M secondary offeringDecember 12, 2024 | msn.comCalidi Biotherapeutics (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer CareDecember 9, 2024 | theglobeandmail.comCalidi Biotherapeutics (NYSE American: CLDI) Showcases RTNova Virotherapy BreakthroughNovember 19, 2024 | theglobeandmail.comCalidi Biotherapeutics Reveals Promising Virotherapy DataNovember 18, 2024 | markets.businessinsider.comCalidi Biotherapeutics: Innovative Cancer Treatment with Promising Clinical Results but Financial ChallengesNovember 18, 2024 | markets.businessinsider.comCalidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung CancerNovember 18, 2024 | markets.businessinsider.comCalidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common StockNovember 15, 2024 | globenewswire.comCalidi prices 4.4M shares at $1.69 in public offeringNovember 14, 2024 | markets.businessinsider.comCalidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common StockNovember 14, 2024 | globenewswire.comCalidi Biotherapeutics Surges on 3Q Report, Retreats on Stock-Offer NewsNovember 14, 2024 | marketwatch.comCalidi Biotherapeutics Announces Proposed Public OfferingNovember 13, 2024 | globenewswire.comCalidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial ResultsNovember 12, 2024 | globenewswire.comCalidi Biotherapeutics’ (NYSE American: CLDI) Groundbreaking Cancer Treatment on RedChip’s Bloomberg TV ProgramOctober 29, 2024 | theglobeandmail.comCalidi Biotherapeutics (NYSE American: CLDI) to Present Antitumor Virotherapy Platform Data at ConferencesOctober 28, 2024 | theglobeandmail.comCalidi to present data supporting RTNova at upcoming conferencesOctober 25, 2024 | markets.businessinsider.comCalidi to sell 2.05M shares at $1.00 in registered direct offeringOctober 24, 2024 | finance.yahoo.comCalidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific ConferencesOctober 24, 2024 | globenewswire.comWhy Calidi Biotherapeutics (CLDI) Stock Is Down 13%October 23, 2024 | benzinga.comCalidi Biotherapeutics stock tumbles on $2M securities offeringOctober 23, 2024 | msn.comCalidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private PlacementOctober 23, 2024 | globenewswire.comCalidi Biotherapeutics Faces Warrant Delisting by NYSEOctober 20, 2024 | markets.businessinsider.comCalidi Biotherapeutics (NYSE:CLDI) Stock Price Up 3.4% - Should You Buy?Calidi Biotherapeutics (NYSE:CLDI) Trading Up 3.4% - Time to Buy?October 19, 2024 | marketbeat.comNYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)October 18, 2024 | globenewswire.comNYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)October 18, 2024 | finance.yahoo.comWendy PizarroOctober 13, 2024 | latimes.comCalidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade GliomaSeptember 30, 2024 | finance.yahoo.comCalidi Biotherapeutics (NYSE:CLDI) Posts Earnings Results, Beats Expectations By $0.03 EPSCalidi Biotherapeutics (NYSE:CLDI - Get Free Report) announced its earnings results on Tuesday. The company reported ($1.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.03.August 14, 2024 | marketbeat.comCalidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial ResultsAugust 14, 2024 | finanznachrichten.deCalidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial ResultsAugust 13, 2024 | globenewswire.comCalidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald RigorJuly 29, 2024 | globenewswire.comCalidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology PlatformJuly 18, 2024 | globenewswire.comCalidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory BoardJuly 16, 2024 | globenewswire.comCalidi to Effect Reverse Stock SplitJuly 5, 2024 | businesswire.comCalidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13June 11, 2024 | businesswire.comCalidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid TumorsJune 10, 2024 | businesswire.comCalidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual MeetingJune 3, 2024 | businesswire.comCalidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross ProceedsMay 31, 2024 | businesswire.com Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDI Media Mentions By Week CLDI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDI News Sentiment▼0.160.49▲Average Medical News Sentiment CLDI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDI Articles This Week▼01▲CLDI Articles Average Week Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aileron Therapeutics News Today Kezar Life Sciences News Today vTv Therapeutics News Today Dyadic International News Today Tonix Pharmaceuticals News Today Actinium Pharmaceuticals News Today SCYNEXIS News Today Iterum Therapeutics News Today Elevation Oncology News Today RAPT Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CLDI) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDI Stock Alerts